ISRCTN40816592 https://doi.org/10.1186/ISRCTN40816592

Effects of Rosiglitazone on fluid retention and insulin resistance in response to Head-out immersion in individuals with type 2 diabetes and impaired glucose tolerance.

Submission date 30/09/2004	**Recruitment status** No longer recruiting	[_] Prospectively registered [_] Protocol [_] Statistical analysis plan [X] Results [_] Individual participant data
Registration date 30/09/2004	**Overall study status** Completed	
Last Edited 15/05/2012	**Condition category** Nutritional, Metabolic, Endocrine	

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Paul O'Hare

Contact details
Diabetes Centre
St Cross Hospital
Barby Road
Rugby
United Kingdom
CV22 5PX

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N0295122840

Study information

Scientific Title

Study objectives
Type 2 diabetes is linked to molecular mechanisms of insulin resistance. Rosiglitazone restores impaired sodium excretion in type 2 diabetes by causing increased insulin sensitivity in the kidneys and within the peripheral vasculature.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Not specified

Study type(s)
Not Specified

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Nutritional, Metabolic, Endocrine: Diabetes

Interventions
Prospective Randomised Controlled Trial.

Intervention Type
Other

Phase
Not Specified

Primary outcome measure

Insulin sensitivity before and after treatment and sodium excretion.

Secondary outcome measures
Not provided at time of registration

Overall study start date
17/07/2002

Completion date
10/12/2004

Eligibility

Key inclusion criteria
Patients with Type 2 Diabetes and impaired glucose tolerance (48).

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
Not provided at time of registration

Key exclusion criteria
Does not meet inclusion criteria

Date of first enrolment
17/07/2002

Date of final enrolment
10/12/2004

Locations

Countries of recruitment
England

United Kingdom

Study participating centre

Diabetes Centre
Rugby
United Kingdom
CV22 5PX

Sponsor information

Organisation
Department of Health

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
University Hospitals Coventry and Warwickshire NHS Trust (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/04/2008		Yes	No